Because Expertise Matters
Join Cyberounds®, an online education community for health professionals Sign Up

Log In

Cardiovascular Medicine

Management of Non-Valvular Atrial Fibrillation – The New Era of Oral Anticoagulants

This presentation may include discussion of commercial products and services. Atrial fibrillation (AF) is defined as a tachyarrhythmia of supraventricular origin leading to deterioration in mechanical function of the...
CME credit is no longer available for this conference.

Course Authors

Muhib Khan, M.D., and Karen Furie, M.D., M.P.H.

Dr. Khan is Assistant Professor and Dr. Furie is Professor and Chair, Department of Neurology, The Warren Alpert Medical School of Brown University, and Neurologist-in-Chief, Rhode Island Hospital, The Miriam Hospital and Bradley Hospital, Providence, RI.

This Cyberounds® program was edited by Mark Crowther, M.D., M.Sc., Professor of Medicine, Pathology & Molecular Medicine and Clinical Epidemiology & Biostatistics, Associate Chair, Department of Medicine, Leo Pharma Chair in Thromboembolism, McMaster University School of Medicine, and Vice President, Research, St Joseph`s Healthcare System, Chief of Laboratory Medicine, Hamilton Health Sciences and St Joseph`s Healthcare, Toronto, Canada.

Within the past 12 months, Drs. Furie and Khan report no commercial conflicts of interest; Dr. Crowther has been on advisory boards for Leo Pharma, Pfizer, Bayer, Boehringer Ingelheim, Alexion, CSL Behring, Portola, Viropharm and AKP Americas, prepared educational materials/presentations for CSL Behring, Celgene, Pfizer and Octapharm, and his institution has received research grant support from Boehringer Ingelheim, Leo Pharma, Octapharm and Pfizer.

Albert Einstein College of Medicine, CCME staff, and interMDnet staff have nothing to disclose.

This activity is certified for cardiovascular medicine, hematology, neurology, primary care (internal medicine, family practice and women’s health), physician assistants, nurse practitioners, nurses, pharmacists, and for all other health professionals interested in the management of atrial fibrillation stroke prevention.

This CME activity has been peer-reviewed by Ileana L. Piña, M.D., M.P.H., Professor of Medicine & Epidemiology and Population Health, Albert Einstein College of Medicine, and Associate Chief for Academic Affairs, Division of Cardiology, Montefiore Medical Center, Bronx, New York.

This activity is made possible by an unrestricted educational grant from Boehringer Ingelheim

Estimated course time: 2 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 
Learning Objectives

Upon completion of this Cyberounds®, you should be able to:

  • Assess the thromboembolic risks associated with atrial fibrillation and apply this knowledge to patient stroke prevention

  • Discuss the data emerging from recent clinical trials of prospective pharmacotherapies and strategies for atrial fibrillation stroke prevention including safety, efficacy and side effects

  • Apply risk stratification in the selection of appropriate therapy (devices, surgeries and pharmacotherapies) for patients with atrial fibrillation.

 

TERMS AND CONDITIONS

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms of this CME activity

Courses You Might Like

Current Management of Hypertension

In 1945, when Franklin D. Roosevelt died of a stroke, little did his physicians know that his long-standing hypertension, with recorded systolic blood pressures as high as 300, had a… major role in his untimely death at the age of 63. The Framingham Heart Study, started in 1949, provided the first insights into the link between elevated blood pressure and cardiovascular disease, with its findings first published in 1961. Since then, numerous studies have provided valuable information about hypertension…
Authors: Aditya Khetan, M.B.B.S., Richard A Josephson, M.S., M.D. and Sri Krishna Madan Mohan M.B.B.S.
Estimated Time: 1 Hour
View Course
More

Myocardial Infarction

This presentation may include discussion of commercial products and services. Significant progress has been made in the primary and secondary prevention of myocardial infarction (MI). Nevertheless, there has been… only a modest reduction in the incidence of myocardial infarction and it remains a leading cause of death. Much effort and energy have been spent on the timely recognition and management of acute MI, in particular emergent reperfusion therapy. This Cyberounds® will focus on the non-emergent and subacute management of…
Authors: Richard Josephson, M.S., M.D., and Sri K. Madan Mohan, M.D.
Estimated Time: 1 Hour
View Course
More

Current Management of Acute Decompensated Heart Failure

The prevalence of heart failure (HF) in the U.S. exceeds six million people. This number will continue to grow with the aging population and increased incidence of… risk factors such as obesity and diabetes. In addition to physical limitations, individuals with HF have a significantly reduced life expectancy even in this era of modern medical therapies. HF hospitalization is one of the strongest predictors of mortality in patients with cardiomyopathy. Up to 30% of those…
Authors: Joel Schilling, M.D., Ph.D.
Estimated Time: 1 Hour
View Course
More

Pharmacological Therapy of Cardiac Arrhythmias: Atrial Fibrillation, Current Treatment and Novel Agents

Cardiac arrhythmias may be seen in individuals with known cardiovascular disease (i.e., coronary artery disease (CAD) or valvular abnormalities) or even in those without known cardiac illnesses. The spectrum… of cardiac arrhythmias varies between more self-limited or minimally symptom atic findings such as palpitations, which may be associated with premature supraventricular or ventricular beats that many experience, to the more worrisome ventricular fibrillation, a known cause of sudden cardiac arrest for which emergency cardiac resuscitation is required. Usually, cardiac arrhythmias…
Authors: Mohan N. Viswanathan, M.D.
Estimated Time: 1 Hour
View Course
More

Cardiac Vagal Neurostimulation for Ventricular Rate Control During Atrial Fibrillation

Atrial fibrillation (AF) is the most common clinically significant cardiac arrhythmia, with an estimated 2.3 million Americans having AF. The prevalence of AF increases with age, reaching… about 9% for those older than 80. Due to the aging of population, the number of AF patients is estimated to increase 2.5 times during the next 50 years. AF accounted for approximately one-third of all hospitalizations with a cardiac rhythm disturbance, and significantly…
Authors: Youhua Zhang, M.D., Ph.D., and Todor N. Mazgalev, Ph.D.
Estimated Time: 1 Hour
View Course
More

Suppression of the Renin-Angiotensin-Aldosterone System

"It is not the answers that enlighten, but the questions." - Ionesco The renin-angiotensin system (RAS) is a major hormonal autocrine/paracrine system that under normal conditions contributes to the regulation of… cardiovascular and renal functions. However, under pathologic condition this system is involved in mechanisms leading to enhanced vasoconstriction, sodium retention, inflammation, matrix formation and cellular hypertrophy. Figure 1. The Renin-Angiotension System. Angiotensin II (Ang II), the major effector peptide of the…
Authors: Samer Ellahham, M.D. and Helmy M. Siragy, M.D.
Estimated Time: 1 Hour
View Course
More